Here are some of the largest recent moves: platform of bispecific gamma delta T cell engagers, announced dosing of the first patient in the Phase 1, first-in-human study of the CD123-targeted ...

LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with Vγ9Vδ2-T cells using LAVA’s Gammabody ® platform. The bsTCE was designed to lyse CD123+ tumor ...

10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of ...

About LAVA-1266 LAVA-1266 is a potent bi-specific, T cell engager (bsTCE) that targets CD123+ tumor cells with V?9Vd2-T cells using LAVA's Gammabody ® platform. The bsTCE was designed to lyse ...

10, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, "LAVA,” "the Company”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody ® platform of ...

“We are pleased to announce the dosing of the first patient with LAVA-1266, a potent and selective CD123-targeted Gammabody®. Based on the positive results of preclinical models showing tumor ...

SAR443579 (also known as IPH6101) is a tri-functional NKp46/CD16-based anti-CD123 NK cell ... body’s first line of immune defence, which can recognise and destroy cancer cells.